Login to Your Account

Pharma: Other News To Note

Wednesday, August 1, 2012
• Intellipharmaceutics International Inc., of Toronto, said it reached an agreement with London-based AstraZeneca plc to settle all outstanding patent litigation concerning its abbreviated new drug application to commercialize a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release) tablets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription